Martin Shkreli, former head of Turing Pharmaceuticals, refused to answer questions at a congressional hearing focused on the company's drug pricing policy.
He invoked his constitutional right against self-incrimination.
Congress is investigating Turing's 5,000% price increase of a drug, Daraprim, used by many Aids patients.